UR-144
![]() | 此條目可參照英語維基百科相應條目來擴充。 (2024年6月5日) |
![]() | |
臨床資料 | |
---|---|
商品名 | different brandnames, typical example: "TMCP-018", "KM-X1", "UR-144", "MN-001", "YX-17" |
法律規範狀態 | |
法律規範 |
|
識別資訊 | |
| |
CAS號 | 1199943-44-6 ![]() |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C21H29NO |
摩爾質量 | 311.47 g·mol−1 |
3D模型(JSmol) | |
| |
|
UR-144(也稱TMCP-018,KM-X1,MN-001,YX-17)是一種含氮有機化合物,分子式C21H29NO,由美國雅培公司開發[2],可作為大麻素受體2的完全激動劑。
參考文獻
- ^ Anvisa. RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-07-24 (2023-07-25) [2023-08-27]. (原始內容存檔於2023-08-27) (巴西葡萄牙語).
- ^ WO application 2006069196,Pace JM, Tietje K, Dart MJ, Meyer MD,「3-Cycloalkylcarbonyl indoles as cannabinoid receptor ligands」,發表於2006-06-29,指定於Abbott Laboratories
外部連結
- Poso A, Huffman JW. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. British Journal of Pharmacology. January 2008, 153 (2): 335–346. PMC 2219524
. PMID 17982473. doi:10.1038/sj.bjp.0707567.
- Chin CL, Tovcimak AE, Hradil VP, Seifert TR, Hollingsworth PR, Chandran P, et al. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. British Journal of Pharmacology. January 2008, 153 (2): 367–379. PMC 2219521
. PMID 17965748. doi:10.1038/sj.bjp.0707506.
- Frost JM, Dart MJ, Tietje KR, Garrison TR, Grayson GK, Daza AV, et al. Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity. Journal of Medicinal Chemistry. March 2008, 51 (6): 1904–1912. PMID 18311894. doi:10.1021/jm7011613.